NVAX

Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.

Wall Street analysts forecast NVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVAX is 11.25 USD with a low forecast of 6.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Novavax Inc revenue for the last quarter amounts to 70.45M USD, decreased -16.64 % YoY.

Novavax Inc. EPS for the last quarter amounts to -1.25 USD, increased 64.47 % YoY.

Novavax Inc (NVAX) has 952 emplpoyees as of December 15 2025.

Today NVAX has the market capitalization of 1.07B USD.